ZFP30 promotes adipogenesis through the KAP1-mediated activation of a retrotransposon-derived Pparg2 enhancer by W. Chen et al.
ARTICLE
ZFP30 promotes adipogenesis through
the KAP1-mediated activation of a
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Krüppel-associated box zinc ﬁnger proteins (KZFPs) constitute the largest family of mam-
malian transcription factors, but most remain completely uncharacterized. While initially
proposed to primarily repress transposable elements, recent reports have revealed that
KFZPs contribute to a wide variety of other biological processes. Using murine and human
in vitro and in vivo models, we demonstrate here that one poorly studied KZFP, ZFP30,
promotes adipogenesis by directly targeting and activating a retrotransposon-derived Pparg2
enhancer. Through mechanistic studies, we further show that ZFP30 recruits the co-regulator
KRAB-associated protein 1 (KAP1), which, surprisingly, acts as a ZFP30 co-activator in this
adipogenic context. Our ﬁndings provide an understanding of both adipogenic and KZFP-
KAP1 complex-mediated gene regulation, showing that the KZFP-KAP1 axis can also function
in a non-repressive manner.
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KZFPs constitute the largest mammalian transcription factor(TF) family1, with about 400 and 600 members (includingpseudogenes) in human and mouse, respectively2,3. KZFPs
are characterized by the presence of an N-terminal Krüppel-asso-
ciated box (KRAB) domain and an array of the C-terminal C2H2
zinc ﬁnger domains4. The KRAB domain typically recruits the co-
repressor KRAB-associated protein 1 (KAP1, also known as
TRIM28, Tif1β), which serves as a scaffold protein for the further
recruitment of co-repressors5. The C2H2 zinc ﬁnger domains
determine a KZFP’s DNA-binding speciﬁcity, with each zinc ﬁnger
typically, but not always6, recognizing three DNA bases7. The
amino acids in positions 1, 2, 3, and 6 in the alpha helical region
of each zinc ﬁnger directly interact with the DNA, thus acting as
the most critical binding speciﬁcity determinants8,9, referred to
as ﬁngerprint10. The KZFPs with similar ﬁngerprints are likely
to recognize similar DNA sequences. However, the exact DNA-
binding speciﬁcity of most KZFPs is yet to be determined.
Despite their abundance, most KZFPs have not been functionally
characterized4. KZFPs have been shown to play roles in some
processes, such as genomic imprinting, cell differentiation, meta-
bolic control, and sexual dimorphism1. However, since the KRAB-
binding co-repressor KAP1 and several KZFPs were found to be
essential for the repression of transposable elements (TEs) in early
embryonic development11–17 and also adult tissues18,19, it has been
proposed that the primary role of KZFPs is to control TE invasion.
We have recently uncovered one poorly studied KZFP, ZFP30, as
a top hit in a large-scale TF overexpression screen aimed at iden-
tifying novel pro-adipogenic regulators20. This ﬁnding suggests that
ZFP30 may be a thus far unrecognized component of the adipo-
genic regulatory network. The latter is one of the better char-
acterized differentiation networks, as many years of research using
especially in vitro cellular models such as 3T3-L1 cells21 have
greatly advanced our understanding of adipogenic gene regulation.
In essence, the principal network components are the TFs C/EBPβ
and C/EBPδ that activate the expression of the adipogenic master
regulators C/EBPα and PPARγ22,23. The latter TF, which is present
as two isoforms (PPARγ1 and PPARγ2) with only PPARγ2 being
restricted to adipose tissue24, is both necessary and sufﬁcient for
adipogenesis since it directly regulates the majority of adipocyte-
speciﬁc genes25. This may explain why Pparg is itself regulated by a
complex network of pro-adipogenic TFs26–28.
It is clear, however, that our understanding of the adipogenic
regulatory network is still far from complete, as also revealed
by our recent genome-wide screen that identiﬁed several unex-
pected adipogenesis-regulating TFs20. In particular, the KZFP
ZFP30 stood out as one of the top adipogenesis-enhancing can-
didates. Here, we demonstrate its critical role in adipogenesis
using murine in vitro and in vivo models, as well as human
stromal vascular fraction (SVF) cells. Interestingly, while ZFP30
targets retrotransposons and acts through KAP1, consistent
with our canonical understanding of KZFP action, its role is to
activate rather than to repress Pparg2 expression and thus adi-
pogenesis. We further show that this surprising activating role
of the ZFP30–KAP1 complex is dependent on ZFP30-mediated
recruitment to an ancient retrotransposon located upstream of
the Pparg2 promoter. Together, our results provide a functional
characterization of the KZFP ZFP30, revealing its target land-
scape, DNA-binding speciﬁcity, detailed mode of action at the
Pparg2 locus in the context of adipogenesis, and evolutionary
relation with speciﬁc retrotransposons.
Results
ZFP30 is a positive regulator of adipogenesis. The KZFP ZFP30
ranked second among the endogenously expressed TFs enhancing
3T3-L1 fat cell differentiation20. We thus explored (1) whether
ZFP30’s role in adipogenesis is general and (2) what the under-
lying regulatory mechanisms are. To validate the screen data,
we reduced Zfp30 expression by lentivirus-mediated shRNA in
3T3-L1 cells and then induced adipocyte differentiation (see
the Methods section). We observed striking differences in lipid
accumulation (as assessed by Oil Red O—ORO—staining)
(Fig. 1a; Supplementary Fig. 1A), which correlated with Zfp30
expression levels (lipid accumulation versus relative Zfp30
expression, Pearson’s r= 0.94, p= 0.017, Supplementary
Fig. 1A). Consistently, the expression level of the adipogenic
marker genes Pparg2, Adipoq, and Fabp4 were signiﬁcantly lower
(p < 0.01, t test) in Zfp30 knockdown (KD) cells compared with
the control (Fig. 1b).
We next generated Zfp30 knockout (KO) cells using CRISPR/
Cas929,30. However, we found that both KO and wild-type cells
generally lost their differentiation capacity, potentially due to
their extended culture upon expansion from single clones31.
Given that the core white and brown adipogenic differentiation
programs are largely shared32, we isolated a clonal subline from
an immortalized murine-derived brown pre-adipocyte cell line
(IBA)33. We found that these subcloned IBA cells constitute a
suitable model alternative to 3T3-L1 cells given that they (i) do
not express the brown adipocyte marker gene uncoupling protein
1 (Ucp1) when differentiated (Supplementary Fig. 1B), (ii)
accumulate large amounts of lipids when induced with the
adipogenic induction cocktail MDI (3-isobutyl-1-methylxanthine,
dexamethasone, and insulin), and (iii) maintain a high differ-
entiation potential even after long-term culture. Using CRISPR/
Cas9, we successfully obtained four Zfp30 mutant clones
(Supplementary Fig. 1C). Based on remaining Zfp30 mRNA
expression levels (Supplementary Fig. 1D), these are expected to
express largely truncated, loss-of-function proteins, which is
why we annotate them as Zfp30 KO cells. We also generated ﬁve
WT clones as controls. Zfp30 mRNA levels in the WT cells were
maximal at conﬂuence, sharply decreased upon MDI exposure,
almost fully recovered at day 1, and ﬁnally stabilized at about half
of the initial value after differentiation day 2 (Supplementary
Fig. 1D). After adipogenic differentiation, four out of the ﬁve
WT and none of the KO IBA clones accumulated large amount
of lipids (Fig. 1c; Supplementary Fig. 1E). The distinct
differentiation capacity in KO and WT was not driven by
differences in cell growth or proliferating rate, since the cell
numbers were comparable after differentiation (Supplementary
Fig. 1F). Consistently, the expression of adipogenic marker
genes was signiﬁcantly lower in Zfp30 KO compared with
WT cells (Fig. 1d; Supplementary Fig. 1G).
To investigate ZFP30 function in vivo, we attempted to
generate Zfp30 KO mice using Zfp30-targeted ES cells obtained
from the European Conditional Mouse Mutagenesis Program34
(Zfp30tm3e(EUCOMM)Hmgu, termed Zfp30tm3e) (Supplementary
Fig. 1H). The homozygous mice (Zfp30tm3e/tm3e) were viable
but, surprisingly, Zfp30 was still expressed in most of the tissues,
including subcutaneous and visceral fat (Supplementary Fig-
ure 1I). Sequencing of the whole targeting cassette showed that all
essential elements were intact. This suggests that the targeting
cassette lost its function in this particular genome context,
through a combination of bypassing the transcriptional termina-
tion site and splicing out of the construct. We therefore resorted
to a previously described in vivo adipogenesis model35 to test the
function of ZFP30 in vivo. Brieﬂy, SVF cells from mouse fat tissue
were transduced with Zfp30 or control shRNA. They were then
embedded into Matrigel and transplanted into the subcutaneous
layer of the mouse neck. The Matrigel pads were analyzed after
subjecting the mice to 6 weeks of high-fat diet. We observed a
signiﬁcant (p= 0.001, paired t test) reduction of the ratio of fat
containing cells to the total cells in Zfp30 KDs (Fig. 1e, f).
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As ZFP30 is highly conserved between mouse and human (82%
similarity, Supplementary Fig. 1J), with an almost identical
ﬁngerprint10 (Supplementary Fig. 1K), we tested whether it also
promotes adipogenesis in humans. We therefore isolated primary
SVF cells from human lipoaspirate samples as previously
described36 and differentiated them with a hormonal cocktail,
analogous to the mouse setup (see the Methods section). When
ZFP30 levels were reduced by lentivirus-mediated shRNA, upon
adipogenesis, we observed a signiﬁcant (p < 0.01, p < 0.05, paired t
test) decrease in both lipid accumulation (based on BODIPY
staining) (Fig. 1g, h) and adipogenic marker gene expression
(Fig. 1i) for three out of the four shRNAs that successfully
reduced ZFP30 expression. The observed difference was not
driven by distinct proliferation rates, as overall cell numbers were
comparable across differentiated samples (Supplementary Fig. 1L).
We then performed a rescue experiment by introducing an
shRNA-resistant ZFP30 (code-optimized and without the 3′UTR
targeted by shRNA-1), while endogenous ZFP30 was knocked
down. As shown in Fig. 1j, k, the introduction of the shRNA-
resistant ZFP30 restored the differentiation of human SVF cells to
control levels, as assessed by lipid accumulation (BODIPY
staining). In sum, we demonstrate that ZFP30 positively regulates
adipogenesis in distinct murine in vitro and in vivo models as
well as in ex vivo human cells.
ZFP30 regulates multiple targets during adipogenesis. To
globally characterize ZFP30’s target landscape, we performed
transcriptomic analyses after Zfp30 reduction or absence, in 3T3-
L1 and in IBA cells, respectively. We reasoned that shared
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differences are most likely to be relevant for understanding the
direct action of Zfp30 on fat cell differentiation, removing unre-
lated cell type-speciﬁc effects. Since we already observed a sig-
niﬁcant (p < 0.01, t test) reduction in adipogenic marker gene
expression in Zfp30 KD samples after 2 days of adipogenic
induction (Supplementary Fig. 2A), we included day 0 and day 2
measurements in both 3T3-L1 and IBA cells, and two additional
time points (2 h and day 4) in IBA cells. Importantly, we found
that the core adipogenic gene program was highly upregulated in
day 2 or 4 (2/4) compared with day 0 samples in both cell models
(Supplementary Fig. 2B,C and Supplementary Data 1). Speciﬁ-
cally, Pparg, Plin4, Lipe, and Cd36 were among the top 30 induced
genes upon differentiation (Supplementary Fig. 2B), and overall,
the upregulated genes enriched for GO terms related to adipo-
genic functions (Supplementary Fig. 2C and Supplementary
Data 2). This validates our earlier ﬁnding that both employed cell
models are appropriate for studying the core adipogenic tran-
scriptional program.
We quantiﬁed signiﬁcant differences in terms of gene
expression between WT and Zfp30 KD/KO samples, at each
individual time point (i.e., day 0, day 0, 2 h, day 2, and day 4)
(DESeq2, FDR <= 0.1 and |FC| >= 2, Methods). We found that
several hundreds of genes were deregulated when Zfp30 levels
were altered (Fig. 2a–f). In general, and most strikingly in KO
samples, more differences were observed upon adipogenic
differentiation, with over 600 genes being up- or downregulated,
respectively, at days 2/4. Overall, we found similar proportions of
up- and downregulated genes, with 150 genes consistently up- or
downregulated in both KO and KD samples, suggesting a
context-speciﬁc action of ZFP30 (Fig. 2a, d). Downregulated
genes enriched for fat cell-related functionality, including GO
terms such as brown fat cell differentiation, triglyceride
biosynthetic process, and triglyceride homeostasis (Fig. 2b;
Supplementary Data 2). The adipogenic marker genes Adipoq,
Cidec, Cebpa, Fabp4, Lipe, Retn, and Fmo1, were among the top
30 genes most reduced in both KD and KO samples (Fig. 2c). In
contrast, upregulated genes were not previously connected to
adipogenesis, enriching for GO terms related to inﬂammatory,
immune, and external stimuli response as well as ossiﬁcation
(Fig. 2e, f; Supplementary Data 2).
To distinguish between direct and indirect effects of ZFP30, we
further set out to determine its genome-wide DNA-binding
landscape using ChIP-seq. As neither the commercial ZFP30
antibodies nor four batches of customized ZFP30 antibodies
recognized it speciﬁcally, as tested by immunoprecipitation, we
performed ChIP-seq in 3T3-L1 cells expressing HA-tagged ZFP30
in a tetracycline-inducible manner, as also previously employed
for ZEB120. The mRNA expression of exogenous Zfp30 was
induced to a similar level as the endogenous Zfp30 by adjusting
the amount of Doxycycline, to avoid potential artefacts due to
protein overexpression. Our replicate HA-ZFP30 ChIP-seq
experiments revealed limited binding (< 100 binding events,
referred to as peaks) at day 0, but up to 400 peaks at day 2 of
adipogenesis (Fig. 2g; Supplementary Fig. 2D) (Methods).
Replicate experiments showed high ChIP enrichment correlations
compared with IgG controls, with a clear separation of ChIP-ed
factor ﬁrst and days (0 vs. 2) second (Supplementary Fig. 2E and
Supplementary Data 3).
To further conﬁrm the speciﬁcity of our ZFP30 ChIP-seq
assays, we reconstituted the Zfp30 KO IBA cells with wild-type
ZFP30 as well as with a mutant lacking the DNA-binding zinc
ﬁnger domains (ZFP30-ΔZF) (Supplementary Fig. 2F). We
observed two bands in the ZFP30-ΔZF mutant sample, indicating
the potential presence of a post translational modiﬁcation. We
then performed ChIP assays on these cells using an anti-HA
antibody and measured the binding enrichment at four distinct
ZFP30-bound regions by qPCR. As shown in Supplementary
Fig. 2G, the ZFP30-ΔZF mutant failed to bind to all of the four
tested loci (the enrichment was indistinguishable from the
negative control), experimentally validating both the reproduci-
bility and speciﬁcity of the ZFP30 ChIP-seq data.
We found that the majority of regions targeted by ZFP30 were
signiﬁcantly more bound at day 2 compared with day 0 (Fig. 2h;
Supplementary Fig. 2H and Supplementary Data 4), (FDR <= 0.15
and |FC| >= 2, Methods). Thus, while ZFP30 binding seems
independent of terminal adipogenesis at some genomic locations,
such as the Oas1 gene cluster, many other genes such as Glis3 and
Myof are only bound by ZFP30 upon adipogenic induction (Fig. 2i;
Supplementary Fig. 2I). This observation suggests that the overall
chromatin structure of day 2 speciﬁcally bound regions may be
more dynamic than that of other bound regions, as also recently
described elsewhere37. Indeed, we found that day 2-speciﬁc ZFP30-
bound locations were increasingly DNase I hypersensitive38 across
early adipogenesis (day 0 to 2 h, 4 h, and day 2), and also showed an
increase in the enhancer-speciﬁc H3K4me1 histone modiﬁcation39
(Fig. 2j). These patterns were much less pertinent at invariant
ZFP30-bound locations (Supplementary Fig. 2J).
To assess how many genes may be directly bound and
regulated by ZFP30, we combined our ChIP-seq and RNA-seq
datasets (Supplementary Fig. 2K). Overall, genes responding to
Zfp30 expression reduction were about two times more likely to
be bound compared with all expressed genes, and genes repressed
by ZFP30 at adipogenic day 2 were even more enriched for ZFP30
binding (Supplementary Fig. 2K).
Fig. 1 ZFP30 is a positive regulator of adipogenesis. a Effect of knocking down (KD) Zfp30 or the negative control (shControl) on 3T3-L1 adipogenic
differentiation as assessed by lipid accumulation (ORO staining). Corresponding Zfp30 expression levels measured by qPCR are displayed below. b Zfp30
and adipogenic marker gene expression upon Zfp30 KD post adipogenic differentiation. n= 3 biologically independent experiments. **p < 0.01, t test.
c Effect of knocking out Zfp30 on IBA adipogenic differentiation as assessed by ORO staining. Five wild-type (WT) and four KO clones are shown.
d Adipogenic marker gene expression in control (c1) and Zfp30 KO (c7) IBA cells post differentiation. n= 3 biologically independent experiments. **p <
0.01, t test. e, f Adipocyte differentiation in stromal vascular fraction (SVF) transplants of three distinct mice fed a high-fat diet for 6 weeks (Methods).
e Fat pad sections from representative samples of Zfp30 KD and control SVF transplants stained with Haematoxylin (blue) and Eosin (pink). Scale bar:
100 µM. f Fat cell content (percent differentiated adipocytes) of the transplanted SVF cells containing Zfp30 KD and control constructs; n= 3 biologically
independent experiments. **p < 0.01, paired t test. g Effect of ZFP30 KD and control on primary SVF cells from human lipoaspirate samples as assessed
by lipid accumulation (BODIPY, green; Hoechst nuclear staining, blue), scale bar 50 µm. Representative images of three independent experiments are
shown. h The fraction of differentiated cells per each shRNA sample shown in (g) (left, **p < 0.01, *p < 0.05, paired t test) and corresponding Zfp30
expression levels (right) as assessed by qPCR. i ADIPOQ expression per each shRNA sample shown in (g). n= 3 biologically independent experiments.
**p < 0.01, *p < 0.05, t test. j Rescue of shZFP30 by introducing shRNA-resistant and code-optimized ZFP30. Experimental settings are similar to (g). Left:
representative images are shown. Middle: the endogenous ZFP30 mRNA level is shown by qPCR. Right: the exogenous HA-ZFP30 protein is shown by
western blotting. k The fraction of differentiated cells for each sample shown in (j). n= 3 biologically independent experiments. *p < 0.05, t test. All panels:
error bars—SD. Source data are provided as a Source Data ﬁle
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Fig. 2 ZFP30 regulates multiple targets during adipogenesis. a, d Number of genes signiﬁcantly (FDR 0.1, |FC| 2) down- (a) or up- (d) regulated upon Zfp30
KD in 3T3-L1 cells at days 0 and 2 upon adipogenesis (left) as well as Zfp30 KO in IBA cells at days 0, days 2, and 4 upon adipogenesis (right) (light gray).
The number of commonly deregulated genes is depicted in dark gray. b,e Gene Ontology (GO) biological processes enriched among the genes commonly
down- (b) and up- (e) regulated upon Zfp30 KD and KO at days 2 or 4. c, f Heatmap displaying the top 30 genes commonly down- (c) and up-
(f) regulated upon Zfp30 KD and KO at days 2 or 4, ordered based on FCs in day 2 KD samples. g Number of ZFP30-HA ChIP-seq peaks in 3T3-L1 cells at
days 0 and 2. Two biological replicates (R1 and R2) were performed. h The overlap between ZFP30-HA ChIP-seq peaks at days 0 and 2. i Examples of
ZFP30-HA DNA binding at the Oas1 gene cluster (adipogenic-invariant binding) and Glis3 locus (adipogenesis-induced binding). j DNase I hypersensitivity
(upper panel) and H3K4me1 (lower panel) signal upon adipogenic induction in a 4 kb window centered around the point of maximal ZFP30 binding,
at locations bound by ZFP30 at day 2 only. k Top de novo motif (M1) discovered in DNA sequences bound by ZFP30 in mouse 3T3-L1 cells. l In vitro
ZFP30 binding to DNA oligos bearing the consensus M1 motif as well as a control sequence, as assessed using MITOMI. The quantities of bound DNA
are expressed in relative ﬂuorescent units (RFU), normalized by protein amount. n= 3 biologically independent experiments. **p < 0.01, t test. m Top
de novo motif discovered in DNA sequences bound by ZFP30 in human HEK239T cells. All panels: error bars—SD. Source data are provided as a
Source Data ﬁle
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We next characterized the sequence speciﬁcity of the ZFP30-
DNA interaction by performing motif discovery on genomic
locations bound by ZFP30 in at least two samples across time
points (Methods). The top two highly enriched motifs (termed
M1 and M2, E= 10−127 and E= 10−52, AUC > 0.74, Fig. 2k;
Supplementary Fig. 2L–O, and Methods) have not been
previously described. As suggested by their similarity and the
fact that their genomic matches are highly overlapping, M2
appears to be a more permissive variant of M1, as also suggested
by its lower information content and the higher fraction of ZFP30
peaks that contain a signiﬁcant M2 match (Supplementary
Fig. 2O). To test if ZFP30 targets M1 directly, we performed a
modiﬁed version of a mechanically induced trapping of molecular
interactions (MITOMI) experiment40,41. We used the M1
consensus sequence as well as a control oligonucleotide across
four distinct concentrations. We found that in vitro, the ZFP30
zinc ﬁnger domains signiﬁcantly (p < 0.01, t test) bind the M1
consensus motif, supporting the notion that ZFP30 binds M1-
containing sites directly in vivo (Fig. 2l).
Given ZFP30’s high human–mouse conservation (Supplementary
Fig. 1J, K), one would expect it to show a similar DNA-binding
speciﬁcity in humans. To test this, we resorted to the easy-to-use
human HEK293T cells, considering that TF-binding motifs are in
any case rarely tissue speciﬁc. Speciﬁcally, we applied ZFP30-HA
ChIP-exo, since it tends to allow a greater resolution in identifying
TF-binding sites, which beneﬁts overall motif discovery (Methods).
We then performed motif discovery on the 2582 detected bound
genomic regions, similar to the above. We observed relatively broad
peaks, which may reﬂect a suboptimal digestion by exonuclease
(Supplementary Fig. 2P). However, both motif and ChIP-seq reads
showed a strong central enrichment at these bound regions,
suggesting the high speciﬁcity of our data (Supplementary Fig. 2P,
Q). Indeed, the top enriched motif (Fig. 2m, E= 10−415, hit rate=
64%, Methods) was a slightly shorter version of the mouse M1, which
was, as expected, highly predictive of ZFP30 binding in mouse (AUC
= 0.72, Methods) (Supplementary Fig. 2N).
Finally, we explored which TFs may collaborate in terms of
DNA binding with ZFP30. To address this, we ﬁrst performed
an additional motif discovery analysis using HOMER ﬁndMotifs42,
which revealed signiﬁcant enrichment of a range of adipogenesis-
associated motifs in ZFP30-bound regions, including NF1, FOSL2,
ATF3/4, and C/EBPbeta20,23,27,32 (Supplementary Data 5). Second,
we tested co-binding of ZFP30 with other TFs previously probed
in 3T3-L1 cells20,38,39,43,44. We found that over one-fourth of ZFP30
peaks co-localized with adipogenic factors, such as C/EBPalpha,
C/EBPbeta, ZEB1, and RXR, indicating potential co-regulation with
these TFs (Supplementary Figure 2R).
ZFP30 directly enhances Pparg2 expression in adipogenesis.
One of the key functions of KZFPs is to target and modulate the
transcriptional inﬂuence of transposable elements4. We therefore
asked if ZFP30 also shows a similar behavior. Indeed, we found that
both in mouse and human, ZFP30 binding is enriched in speciﬁc
subsets of LINE1 elements, in particular L1MEg and L1MEd (Fig. 3a;
Methods and Supplementary Data 6). Interestingly, L1MEd are
among the oldest members of the L1 family, with an estimated age of
~150 million years45. It is thus conceivable that ZFP30, with its
estimated age of ~105–150 million years46 may have co-evolved with
these L1 repeats. We then examined the TEs regulated by ZFP30 by
analyzing the RNA-seq data from 3T3-L1 cells. While we found that
there are ~600 TEs differentially expressed in shZFP30 samples in
both day 0 and day 2 (Supplementary Fig. 3A), none of them is
bound by ZFP30. These ﬁndings suggest that ZFP30 does not act as
a direct repressor of these still active TEs. This is further supported
by the short length of ZFP30-bound L1s, suggestive of their decay
(Supplementary Fig. 3B).
To gain better insight into ZFP30’s role at its retrotransposon
targets, we inspected expression patterns of genes proximal/
overlapping L1-associated ZFP30 peaks (Fig. 3b). Similar to the
general results reported above, we found that Zfp30 KO/KD
resulted in both up- and downregulation of nearby targets,
suggesting context-speciﬁc effects. For instance, the genes in the
Oas cluster, known for their role in immunity to viral
infections47, contained a bound L1MEd element and were
upregulated in response to Zfp30 KD. In contrast, the master
adipogenic regulator Pparg contained an L1MC5a-associated
ZFP30 peak and was signiﬁcantly downregulated in the absence
of ZFP30. Thus, suppression of Zfp30 expression does not only
result in upegulation but also in downregulation of proximal
target genes. Given the old age of its target retrotransposons, it is
likely that over time, at the mentioned locations, ZFP30 was
eventually co-opted into the local gene regulatory network as
either activator or repressor, after its transposable element-
repressive role was no longer required due to the mutation-driven
inactivation and divergence of the L1 elements.
To explore this hypothesis in greater molecular detail, we
further investigated the ZFP30-targeted and regulated genes
(Supplementary Fig. 2K). We found that while there were
79 genes bound and up- or downregulated in KD or KO samples
(Supplementary Fig. 3C), which represents a signiﬁcant enrich-
ment (p= 0.003) compared to a randomized control (1000
repeats), 12 of them showed a consistent response across 3T3-L1
and IBA cells (Fig. 3c). While more genes bound and regulated
by ZFP30 in both KO and KD samples were upregulated
when Zfp30 levels were reduced, we found that three known
adipogenesis-associated genes were likely to be directly activated
by ZFP30: Cidec, Angptl4, and most notably, Pparg (Fig. 3c).
To validate that ZFP30 regulates these genes directly, we
performed luciferase reporter assays. We successfully cloned the
bound DNA fragments (~700 bp) of Plscr2, Tec, Col28a1, Myof,
Ahnak, Pparg, Angptl4, and Cidec into the pGL3-promoter vector.
While the Myof fragment is derived from the promotor region,
others are either intronic or distal intergenic regions. Reporter
activities were measured in Zfp30 KD and control 3T3-L1 cells, both
in undifferentiated and differentiated (day 2) conditions using the
empty pGL3-promoter vector as a negative/baseline control (Fig. 3d).
Half of the reporters were consistently regulated irrespective of
differentiation status, and the direction of regulation corresponded to
the direction predicted based on the RNA-seq data. Speciﬁcally,
Pparg and Angptl4 reporter activity was lower upon Zfp30 KD,
whereas that of Tec and Myof was higher. Three other reporters
(Plscr2, Col28a1, and Ahnak) showed differentiation-speciﬁc activity,
while only Cidec showed no response in our assays. Together with
the RNA-seq and ChIP-seq analyses, these results suggest that,
while ZFP30 may indeed act most often in a repressive manner as
expected from a KZFP, there are several genomic locations at which
it activates transcription. Importantly, the latter includes the master
adipogenic regulator, Pparg.
To validate further ZFP30’s role in enhancing Pparg expres-
sion, we aimed to test its activity in a setting that maintains the
regulatory element–promoter interaction48. ZFP30 binds a
genomic site that is highly conserved across ~100 million years
of evolution (human to armadillo), which was derived from a
L1MC5a element, located about 9 kb upstream of the Pparg2
transcription start site (Fig. 3e). In mouse, the larger region was
disrupted by a more recent (rodent-speciﬁc) B3A element
insertion, that occurred downstream of the ZFP30 motif, which
itself remained intact. To validate that ZFP30 targets this speciﬁc
motif instance, we again performed MITOMI experiments, this
time using the exact genomic sequence at the Pparg2 locus rather
than the consensus motif, as well as a negative control. Our
experiments revealed that this sequence is signiﬁcantly (p < 0.01, t
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test) and directly bound by ZFP30’s zinc ﬁnger domains in vitro
(Fig. 3f). We then tested ZFP30’s potential impact on local
L1MC5a expression. Given the heavily decayed nature of this
TE, we reasoned that the transcript derived from this TE would
not be detected by our polyA-enriched RNA-seq protocol
(Supplementary Fig. 3A), even if expressed. This is why we
performed RT-qPCR of this locus using a random hexamer
for reverse transcription, revealing that the TE-derived transcript
is indeed expressed, while being largely reduced in Zfp30 KO
cells (Supplementary Fig. 3D). These data indicate that ZFP30
chr6:
ZFP30-HA ChIP-seq
GENCODE M16 (ensembl 91)
PpargPparg
Luc
TSS
Luc
TSS
Luc
TSS
Pparg2
TSSZFP30 binding peak
ZFP30 binding motif
Pparg2-P
Pparg2-PdM
Pparg2-PdP
D0 D2 D0 D22H D4
Olr1
Plscr2*
Kcnk2*
Tec*
Col28a1
Myof*
Gm20488*
9330154J02Rik*
Ahnak*
Pparg*
Angptl4
Cidec*
L1
M
E1
L1
_M
ur
3
ID
_B
1
R
LT
R
17
B_
M
m
L1
M
4
L1
M
Eg
L1
M
Ed
Lo
g2
 Z
FP
30
/
sh
ift
ed
0
2
4
L1
M
D
a
L1
M
Ec
L1
M
4a
1
L1
M
Ei
L1
P4
a
L1
M
Eg
L1
M
Ed
Lo
g2
 Z
FP
30
/
sh
ift
ed
0
2
4
D0 D2 D0 D22H D4
Oas1a*+
Oas1g*
Oas1b*
Oas1c*+
Kif5c*+
Rb1
Pde10a*
Mapk9
Zfp148
Ttc7b
Tank
Zfp119a
Ttc17
Vti1a
Rcbtb2
Exoc6b
Lpp
Cwc22
Evc*+
Phf2
Serinc5
Lrp6
Tcf4+
Sema6d*
Antxr1*+
Slc38a4*
Pparg*+
Mouse Human
**
**
**
**
20 kb mm10
115,370,000 115,380,000 115,390,000 115,400,000 115,410,000 115,420,000
Gaps
Mouse
Rat
Human
Pig
Dog
Elephant
Armadillo
Opossum
Tasmanian_devil
Wallaby
Chicken
Painted_turtle
TTATAAACCCAAATCATTTATTTGGAGAAGAGATGATGAAGGTTTTAGAACCCTAAGCAGAATGATTATTGAAACTGAGTGTCAGGGTGAGGGAGCTAGCTTAGCAGT
ZFP30-HA 
Multiz alignments of 60 vertebrates
RepeatMasker 
ZFP30 motif M1
Mam.repeats
5 9 1 3 1 1
TTATAAACCCAAATCATTTATTTGGAGAAGAGATGATGAAGGTTTTAGAACCCTAAGCAGAATGATTATTGAAACTGAGTGTCAGGGTGAGGGAGCTAGCTTAGCAGT
TTATAAACTCAAATTATTGATTTGGAGAAGATATGATCAAGTTTTTAGAATCCTAAGCGGAATGATTATTGAAACTGAATGCCAGG- TGTGGGAGATGGCTTAGTAGT
TCATAAACTCCAAGTATTGATTCAG -GAAAAGATGATAAAGTTTTTACA - CCTTTAGGTGAATGATTAATGAAACTGAACATC - - - - - - - - - - - - - - - - - - - - - - - - -
TAATACACTCAGAGTATTGATTCAG -GAAAAGATGAT - - - - TGTTTAAAACCTTTAAGTGAATGATCGGTGAAACTGA== === = === === === === = === === === = =
TCATTAACTCAAAGTATTGATTCAG -GAGAAGATTATTAAATGTTTAAAA=CTTTAAACGAGCGATTGGTGAAACTGAACGTC= === === === === = === === === = =
TCACAAACTCAAATTACTGATTCAA - GAAAAGATTATCAAGTGTTCAAAACTTCTAGGTGAATAATGGATGAAATTGAACATC= === === === === = === === === = =
- - - - AAACTCAAACTGCTGATTTGG -GAAAAGATGATCAAGTGTTTAAAACTTTTAGGTGAATGATTGATGAAACACAGCATC= === === === === = === === === = =
== === === === = === === === === = === === === = === === === === = === === === === = === === === = === === === === = === === === === = === === === = =
CAGTTA - - CCACATCATTAGTGCAG -GAAAAGATTATCAAGGATT - - - - -GCTGCAGAGAAAA - ATTTTTGAAA -GGAATGCT - - - - - -GAGGTGAGAGTTTTGCATT
== === === === = === === === === = === === === = === === === === = === === === === = === === === = === === === === = === === === === = === === === = =
== === === === = === === === === = === === === = === === === === = === === === === = === === === = === === === === = === === === === = === === === = =
== === === === = === === === === = === === === = === === === === = === === === === = === === === = === === === === = === === === === = === === === = =
852
B3A#SINE/B2
Placental Cons
3.296 _
–3.94 _
0 -
L1MC5a#L1
115,412,685 115,412,777
B3AL1MC5a
0.0 1.0 2.0 3.0
0.0
1.0
2.0
Concentration (μM)
R
FU
ZFP30 motif at Pparg2
Control
3T3-L1 IBA
c1 c10 c14 c25 c27
c2 c9 c40 c42
Pparg2-M1 KO
WT
Pparg2
ZFP30 motif
TSSCRISPR/Cas9
Pparg2-M1 KO
C9 C4
0
C4
2
0.0
0.5
1.0
1.5
R
el
at
iv
e 
Pp
ar
g2
 
e
xp
re
ss
io
n
Pparg2_M1_KO WT
KD
Control
KO
−2 –9
2 9
log2_expr.
FC D0-D2
−20 2
Row z−score
Norm_expr.
R1
R2
Co
nt
ro
l
Pl
sc
r2
Te
c
Co
l2
8a
1
M
yo
f
Ah
na
k
Pp
ar
g
An
gp
tl4
Ci
de
c
lo
g2
 s
hZ
fp
30
/s
hC
on
tro
l
–1.0
−0.5
0.0
0.5
1.0
Co
nt
ro
l
Pl
sc
r2
Te
c
Co
l2
8a
1
M
yo
f
Ah
na
k
Pp
ar
g
An
gp
tl4
Ci
de
c
–1.0
–0.5
0.0
0.5
1.0
R1
R2
Day 0 Day 2
lo
g2
 s
hZ
fp
30
/s
hC
on
tro
l
0.0
0.1
0.2
0.3
0.4
0.5
Fi
re
fly
/re
ni
lla
D0 D2
**
*
**
pGL3_vector
Pparg2-P
Pparg2-PdM
Pparg2-PdP
0.0
0.2
0.4
0.6
0.8
1.0
shControl shZfp30_pool
pGL3_vector
Pparg2-P
Pparg2-PdM
Pparg2-PdP
Fi
re
fly
/re
ni
lla
**
** **
**
43 bp
3T3-L1 IBA
C1 C1
0
C1
4
C2
5
C2
7 C2
a b
c
d
e
f
g h i
j k
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09803-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1809 | https://doi.org/10.1038/s41467-019-09803-9 | www.nature.com/naturecommunications 7
directly binds to and activates the expression of this decayed
L1MC5a TE.
Next, we cloned a ~9.5 -kb DNA fragment upstream of the
Pparg2 transcription start site (TSS) into a pGL30-basic luciferase
vector (termed Pparg2-P), containing the promoter and the
described ZFP30-bound region (peak) and motif. We also
generated mutants lacking the ZFP30 peak (Pparg2-PdP) and
ZFP30 motif (Pparg2-PdM), respectively (Fig. 3g). We found that
the activity of the full-length reporter was induced when
differentiated, but that of the Pparg2-PdP and Pparg2-PdM
reporters was signiﬁcantly (p= 0.01 and p= 0.03, respectively,
t test) reduced (Fig. 3h). Furthermore, we found that ectopic
expression of ZFP30 tended to increase the activity of the Pparg2-
P, but not the Pparg2-PdM reporter (Supplementary Fig. 3E).
The inverse experiment was even more compelling, since the
difference between the Pparg2-P and the Pparg2-PdM/Pparg2-
PdP reporter activities disappeared when Zfp30 mRNA levels
were reduced by KD (Fig. 3i). Finally, to directly address
whether this reﬂects the function of ZFP30 in its local
endogenous genomic context, we used CRISPR/Cas929,30 to
delete 43 bp of the Pparg genomic locus, including the ZFP30-
binding motif and a few surrounding nucleotides, which, based
on motif scanning, do not contain other relevant TF-binding
sites (Fig. 3j; Supplementary Fig. 3F, Methods). As shown in
Fig. 3k and Supplementary Fig. 3G, KO of the motif reduced
lipid accumulation in four out of ﬁve clones of IBA cells,
compared with the four wild-type clones. Consistently, Pparg2,
Pparg1 and Adipoq expression levels were also signiﬁcantly
reduced in these cells (Fig. 3k and Supplementary Fig. 3G).
Collectively, these results strongly suggest that ZFP30 enhances
Pparg gene expression by directly targeting a retrotransposon-
derived enhancer element.
KAP1 interacts with ZFP30 and promotes adipogenesis. We set
out to investigate how ZFP30 regulates its targets genes, with a
particular focus on Pparg, given ZFP30’s unexpected role in
activating the expression of this adipogenic master regulator. As
a KZFP (Supplementary Fig. 1C), ZFP30 is likely to interact
with KAP15,49. Indeed, we were able to co-immunoprecipitate
ZFP30 with KAP1 when both were overexpressed in
HEK293T cells (Fig. 4a). To further clarify whether this interac-
tion also occurs in an adipogenic environment, we tested it in
3T3-L1 cells. As mentioned before, a ZFP30 antibody was not
available; therefore, we used HA-ZFP30-expressing 3T3-L1 cells,
as described previously for our ChIP-seq assays. Cells expressing
the same empty vector and PPARG were included as controls.
Endogenous KAP1 was pulled down together with HA-ZFP30,
but not with HA-PPARG, validating the interaction between the
two proteins in an adipogenic setting (Figure 4b). The KRAB
domain is well known to mediate the interaction of KZFPs with
KAP1. Indeed, we found that the ZFP30 mutant containing a
KRAB domain deletion (ΔKRAB) fails to interact with KAP1
(Fig. 4c). Interestingly, the mutant (ZFP30-In24aa) with a 24
amino acid insertion in the KRAB domain derived from the
second allele of the Zfp30 KO clone c15 (Supplementary Fig. 1C)
also lost its KAP1-interacting capacity (Fig. 4c). These results
experimentally conﬁrm that ZFP30’s KRAB domain is essential
for its interaction with KAP1, in line with expectations based on
the function of other KZFPs.
Given ZFP30’s role as a pro-adipogenic regulator and the ﬁnding
that the Zfp30 KO clone c15, which expresses a KAP1-interaction-
deﬁcient Zfp30 mutant, also shows low differentiation efﬁciency, we
hypothesized that KAP1 has a similar adipogenic function to ZFP30.
We thus tested this hypothesis by knocking down Kap1 in 3T3-L1
cells. However, the KD led to dramatic cell death (Supplementary
Fig. 4), consistent with previous reports in distinct cellular
environments50,51. In our second model, IBA cells, we did not
observe any signiﬁcant cell death upon Kap1 KD, supporting the
notion that the effect of Kap1 depletion is cell type-speciﬁc. We found
that the differentiation of IBA cells was attenuated upon Kap1
reduction, while reconstitution of Kap1 expression with an shRNA-
resistant KAP1 (Methods) restored the differentiation, as reﬂected by
both lipid accumulation and adipogenic marker expression (Fig. 4d).
We also generated primary mouse embryonic ﬁbroblasts (MEF) cells
from Kap1loxp/loxp mice. Kap1 KO and control cells were generated
from these cells by introducing the Cre recombinase and an empty
vector, respectively. Although no signiﬁcant lipid accumulation was
observed in either of these cells upon an adipogenic stimulus,
probably due to the variable differentiation capacity of MEF cells,
consistent with previous reports26, we detected a signiﬁcant reduction
of adipogenic marker gene expression in Kap1 KO cells compared
with controls (Fig. 4e). Together, these results demonstrate that
ZFP30 interacts with KAP1, and KAP1 itself is required for
adipogenesis across distinct cell types.
ZFP30 activates Pparg2 expression through KAP1. To further
characterize its role in adipogenesis and as a ZFP30 partner, we
performed KAP1 ChIP-seq in undifferentiated (day 0) and dif-
ferentiated (day 2) 3T3-L1 cells, as described above for HA-
ZFP30. We ﬁrst conﬁrmed the high enrichment obtained with the
employed KAP1 antibody (Supplementary Fig. 5A). Replicate
experiments revealed ~300–500 KAP1-enriched regions genome-
wide (Fig. 5a). Correlation analysis between the ChIP-seq
enrichments showed an overall high correlation between the
Fig. 3 ZFP30 directly enhances Pparg2 expression during adipogenesis. a Enrichment of speciﬁc transposable element (TE) types among regions bound by
ZFP30 in mouse 3T3-L1 (left) and human HEK293T (right) cells (Methods). b Heatmap displaying all genes showing proximal (<= 5 kb) TE-associated
ZFP30 binding. *Signiﬁcantly DE in Zfp30 KD,+ signiﬁcantly DE in Zfp30 KO at day 2 or 4. c Heatmap displaying all genes showing proximal ZFP30 binding
and signiﬁcant DE in both Zfp30 KD and KO samples. *Day 2-speciﬁc ZFP30 binding. Same legend as in (b). d Luciferase assay showing the difference in
regulatory activity upon Zfp30 KD in 3T3-L1 (log2 shZfp30/shControl) for distinct sequences targeted by ZFP30. R1, R2—replicates 1 and 2. e Detailed
visualization of the ZFP30-bound region upstream of the Pparg2 promoter, including the ZFP30-HA ChIP-seq read pileup, motif, MITOMI-tested (in vitro)
bound sequence (orange), vertebrate conservation and multiple alignment, as well as TEs (mammalian repeats Mam.repeats, top, brown, and UCSC
RepeatMasker track, bottom, gray). f In vitro ZFP30 binding to the Pparg2motif match (dark orange in E) as well as to a control oligonucleotide as assessed
by MITOMI. n= 3 biologically independent experiments. **p < 0.01, t test. Note that the control curve is shared with Fig. 2l, as the binding assays were
performed on the same MITOMI chips. g Schematic representation of the constructs employed for the luciferase assays displayed in (h, i). Pparg2-P:
full construct; Pparg2-PdM: ZFP30 motif deletion; Pparg2-PdP: ZFP30 peak deletion. h Transcriptional activity as measured by luciferase assays (Fireﬂy/
Renilla) for three distinct constructs shown in (g) as well as the control vector at days 0 and 2 of adipogenic differentiation (h), or at day 2 upon Zfp30 KD
(i). The values of all samples were compared with that of Pparg2-P in each group. n= 3 biologically independent experiments. **p < 0.01, *p < 0.05, t test.
j Schematic of Pparg2-M1 KO cells. k Left: effect of knocking out the ZFP30 DNA-binding motif at the Pparg2 locus on IBA adipogenic differentiation as
assessed by lipid accumulation (ORO staining). Right: corresponding Pparg2 expression levels after differentiation were measured by qPCR. All panels:
error bars—SD. Source data are provided as a Source Data ﬁle
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KAP1 ChIP replicates (Supplementary Fig. 5B), conﬁrming the
quality of our data. Unlike ZFP30, which showed more abundant
binding at day 2, KAP1’s enrichment at these regions was not
strongly modulated by differentiation (Fig. 5a, b; Supplementary
Figure 5C and Supplementary Data 4). Consistent with previous
ﬁndings46,52, KAP1 binding localized more often at genes
coding for KZFPs (Fig. 5c; Supplementary Fig. 5D) and at the 3′
end of genes (Supplementary Fig. 5E), compared with other co-
regulators/TFs, such as p300 and ZEB1. For instance, over 20% of
genes bound by KAP1 encode KZFPs (Supplementary Fig. 5F),
while this is the case for only less than 2% of P300 or ZEB1-
bound genes (p < 10-16, Fisher’s exact test). These results further
validate the quality of our ChIP-seq data.
Interestingly, our data revealed that only a small subset (14,
~3%) of ZFP30-bound regions are also targeted by KAP1. While
most of these regions were gene-proximal, a single location stood
out as proximal to a gene showing a consistent transcriptional
response upon Zfp30’s absence in both 3T3-L1 and IBA cells
(Fig. 3c): the Pparg locus. Strikingly, KAP1 binding mirrored
ZFP30 binding at the Pparg2 enhancer site, with D2-speciﬁc
enrichment for both proteins (Fig. 5d). We found that multiple
active histone marks (including H3K27ac and H3K4me1),
transcriptional coactivators (CBP/p300), as well as RNA Pol II
were also only detected at this location upon adipogenic
differentiation (Fig. 5d). We note that this was the case in both
white and brown fat cell lines38,39,53, suggesting that this
regulatory element has pan-adipogenic speciﬁcity (Fig. 5d).
Our current understanding of KZFP–KAP1 interactions would
suggest that KAP1 is recruited to the Pparg2 locus by ZFP30.
We therefore performed ChIP-qPCR with the KAP1 antibody
in Zfp30 KD and control cells before and after adipogenic
differentiation. Consistent with the ChIP-seq data (Fig. 5d), the
binding of KAP1 increased during differentiation, and this effect
was reduced after Zfp30 KD (Fig. 5e). In contrast, the binding
of KAP1 to the Zfp810 genomic locus, which is not bound by
ZFP30, was not inﬂuenced by a ZFP30 loss of function (Fig. 5e).
Moreover, we found that the recruitment of KAP1 to this
genomic locus is impaired in Zfp30 KO cells reconstituted with
the KAP1-interaction-deﬁcient mutant In24aa (Fig. 4c) compared
with those of wild-type Zfp30 (Supplementary Fig. 5G, H),
excluding the possibility that ZFP30 binds/opens this locus and as
such allows KAP1 to be recruited by other factors. Altogether,
these data indicate that KAP1 is recruited to the Pparg2 enhancer
by ZFP30.
We next tested the function of KAP1 in regulating Pparg2
expression. Since knocking down Kap1 led to cell death in 3T3-L1
but not IBA cells (Supplementary Fig. 4), and KAP1 occupancy
at the Pparg2 enhancer was similar in the two cell lines
(Supplementary Fig. 5I), we used IBA cells. Kap1 KD diminished
Pparg2 enhancer activity, which was reversed by restoring Kap1
expression (Fig. 5f), demonstrating the direct involvement of
KAP1 in regulating Pparg2 expression. Moreover, ectopic
expression of Pparg2 restored the differentiation defect, both in
Kap1 and Zfp30 KD IBA cells (Fig. 5g, h). Together, these results
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Kap1 and of rescuing Kap1 expression on IBA adipogenic differentiation as assessed by lipid accumulation (ORO staining). The rescue of Kap1 expression
was achieved by introducing an shRNA-resistant allele. The expression of endogenous and exogenous Kap1 (endo-Kap1 and exo-Kap1, respectively), as well
as adipogenic marker genes was assessed by qPCR. n= 3 biologically independent experiments. **p < 0.01, *p < 0.05, t test, compared with shControl.
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support our thesis that ZFP30/KAP1 promotes adipogenesis by
directly targeting Pparg2.
Discussion
Most of our knowledge on fat cell differentiation is derived from
studies employing the 3T3-L1 and 3T3-F442A cell models. While
many regulators identiﬁed from these models have proven to
be relevant outside these systems, others still need to be con-
ﬁrmed. For example, p38 promotes adipogenesis in 3T3-L1
cells54, but shows an opposite effect in other models55. Our study
reveals that the poorly characterized KZFP ZFP3056,57 is
important for adipogenesis across different mouse pre-adipocyte
cell lines, an in vivo mouse model and ex vivo human cells, ﬁrmly
establishing it as a pro-adipogenic TF. ZFP30 directly enhances
Pparg2 expression through binding and recruiting KAP1 to a
Pe
ak
 N
rs
.
0
200
400
600
R1 R2 R1 R2
D0 D2
69871 10
D0 D2
Fr
ac
tio
n 
of
pe
ak
s 
at
 K
ZF
Ps
0.0
0.1
0.2
KA
P1
.u
KA
P1
.i
ZF
P3
0
ZE
B1
P3
00
%
 In
pu
t
IgG KAP1
Zfp810
%
 In
pu
t
IgG KAP1
Control
%
 In
pu
t
IgG KAP1
Pparg2
**
shControl D0
shControl D2
shZfp30_Pool D0
shZfp30_Pool D2
**
Dox +
Dox–
Pparg2 Vector
shKap1
shControl
KAP1
ACTB
HA
shKap1
Pp
ar
g2
Ve
ct
or
Dox
-37
-100
-50
ACTB
HA
Pp
ar
g2
Ve
ct
or
Dox
- 50
- 37
Pparg2
Dox–
Dox+
0.0
0.5
Pparg2-P
Pparg2-PdM
1.0
1.5
re
sc
u
e
_K
ap
1
sh
Ka
p1
sh
Co
nt
ro
l
Fi
re
fly
/re
ni
lla
**
**
0.0
0.2
0.4
0.6
0.8
0
5
10
15
0.0
0.2
0.4
0.6
0.8
D0
ZF
P3
0
KA
P1
PO
L2
P3
00
K2
7A
c
ZF
P3
0
KA
P1
PO
L2
P3
00
K2
7A
c
CB
P
K2
7A
c
PO
L2
CB
P
K2
7A
c
PO
L2
D2
D0
D2
Pparg2
W
hi
te
 a
di
po
ge
ne
sis
Br
ow
n 
ad
ip
og
en
es
is
4
4
4
6
3
4
4
4
6
3
2
3
2
2
3
2
H
3K
4
m
e
1
H
3K
4
m
e
1
4
4
115,405 mb
115,41 mb
115,415 mb
115,42 mb
P per g
115,43 mb
115,425 mb
– – –+ + – –+ +
Vector
a b c
d
e
f
g h
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09803-9
10 NATURE COMMUNICATIONS |         (2019) 10:1809 | https://doi.org/10.1038/s41467-019-09803-9 | www.nature.com/naturecommunications
retrotransposon-derived enhancer located 9 kb upstream of the
Pparg2 TSS. Pparg1 may also be regulated by this element,
since its expression is reduced approximately fourfold in cells in
which this enhancer is partially deleted (Supplementary Fig. 3G).
However, the fact that Pparg2 shows a ~50-fold expression
reduction in these same cells suggests that Pparg2 is the primary
regulatory target (Fig. 3k ; Supplementary Fig. 3G). Consistently,
Pparg2 ectopic expression is sufﬁcient to rescue the differentiation
defect in ZFP30- or KAP1-depleted cells (Fig. 5g, h). While
our current study focuses on ZFP30’s role in adipogenesis and the
relation with KAP1 and Pparg2 expression, ZFP30’s function
likely goes beyond a single tissue, as exempliﬁed by its link to
disease phenotypes (Cerebral visual impairment and intellectual
disability, ClinVar)58, and its high expression in tissues, such as
the retina, skin, and muscle (Supplementary Fig. 1I). For instance,
the single experimentally documented role of ZFP30 prior to
our study was its involvement in inﬂammation in the murine
lung56. Our gene expression data align with this ﬁnding, sug-
gesting that ZFP30 represses genes that enrich for inﬂammatory
and immune response-related functionalities (Fig. 2d–f; Supple-
mentary Data 2). Meanwhile, our results suggest that some genes
can be both activated and suppressed by ZFP30, depending on
their cellular context (Fig. 3d).
In our previous screen20, we identiﬁed several zinc ﬁnger
proteins, including ZEB1, ZFP30, and ZFP277 as top hits.
Although all three of them belong to the same TF family, they
appear to regulate adipogenesis through different mechanisms.
Indeed, we found that ZFP277-HA did not even localize to the
cell nucleus, while ZEB1 has a very broad target landscape
compared with a restricted one for ZFP30. The most coherent
regulatory adipogenic signal for ZFP30 pointed clearly to direct
Pparg regulation. Even though Zfp30 is already highly expressed
before differentiation, it binds and activates Pparg2 only after
differentiation. This suggests that ZFP30 is not a pioneer factor in
mediating chromatin access, and that it therefore requires other
TFs to open the chromatin. Moreover, there are several adipo-
genic TF-binding motifs co-enriched in ZFP30-binding sites
(Supplementary Data 5) and ZFP30 shares a large fraction of
binding loci with these factors, which for example include
the adipogenic pioneer factor C/EBPbeta and ZEB120,38,59 at the
Pparg locus (Supplementary Fig. 2R). Based on these collective
results, we propose that ZFP30 is a highly speciﬁc but integral
part of the wider adipogenic gene regulatory network: its binding
is facilitated by prior chromatin opening by C/EBPbeta or other
factors, while it itself recruits KAP1 to increase Pparg2 expression.
Indeed, as a member of the KZFP family, ZFP30 was expected
to act through recruitment of the KAP1-silencing complex49.
The latter contains the HP1, SETDB1, and NuRD complexes,
as well as DNMTs, and mediates chromatin inactivation and/or
DNA methylation. This silencing mechanism was found to be
important for controlling transposable element (TE) activity and
the expression of nearby genes during the early stages of
embryonic development11–14 as well as in some adult tissues18,19.
An evolutionary arms-race model was proposed to explain the
constant competition between KZFPs and their TE targets16:
KZFPs evolve to suppress new TEs, while TEs mutate to evade the
repression, triggering further KZFP evolution. This model may
explain the large amount and diversity of TEs in the genome, with
about 44 and 38% of repetitive DNA in humans and mice,
respectively60, as well as the abundance of KZFPs. Indeed, a recent
large-scale ChIP-seq study showed that most KZFPs bind TEs46.
Consistently, we found that ZFP30 preferentially binds to speciﬁc
subtypes of LINE1 elements, directly targeting L1MEd and L1MEg
elements in particular (Fig. 3a, b), across mice and humans.
However, the arms-race model only partially explains the
evolution of KZFPs and their DNA interaction properties,
because most TE-associated KZFP-binding sequences are far
more conserved than the rest of the elements in which they reside,
and some KZFPs emerged long after their TE had lost any
invading potential46. Supporting a regulatory rather than a purely
inhibitory role for KZFPs, many TE-residing KZFP-binding sites
are enriched for active enhancer marks in a cell type-speciﬁc
manner46. This suggests that over time, certain TE-bound KZFPs
were adopted into the local gene regulatory network to mediate
transcription, similar to other TE-targeting TFs, such as the
master genome regulator CTCF61. Here, we propose that ZFP30
constitutes a prime example of such a possible exaptation pro-
cess18: ZFP30 targets a degenerated LINE-1 (L1MC5a) element
and increases the expression of the nearby gene, the master adi-
pogenic regulator Pparg2. The ZFP30 target site is highly con-
served across ~100 million years of evolution (Fig. 3e) and
contains the newly described ZFP30 DNA-binding motif, which
is required for Pparg2 activation and bound by ZFP30 with high
afﬁnity in vitro. Interestingly, both ZFP30 itself and the trans-
posable element subtypes that it primarily targets (L1MEd and
L1MEg) have been found to stem from overlapping time win-
dows, between 105 and 150 million years ago45,46. This suggests
that ZFP30 may have initially evolved to suppress these elements.
At the Pparg2 locus, its binding to the L1MC5a insert could have
evolved into an adipogenic hotspot44, also targeted and activated
by GR and C/EBPbeta62, which forms a loop to interact with and
activate the Pparg2 promoter63. Whether and how ZFP30/KAP1
function in coordination with the previously identiﬁed hotspot
factors remains to be fully elucidated.
Interestingly and as already mentioned above, we did ﬁnd that
similar to many, though not all KZFPs, ZFP30 binds KAP1.
However, unlike all other KAP1-interacting KZFPs characterized
so far, ZFP30 recruits KAP1 as a co-activator at the Pparg2
enhancer (Fig. 4–5). While KAP1 has previously been shown to
be a co-activator of non-KZFP TFs, such as C/EBPbeta64, NGFI-
B65, and MYOD66, our study shows that the KZFP–KAP1 axis
can also function in a non-repressive manner. Future research
Fig. 5 ZFP30 activates Pparg2 expression through KAP1. a Number of KAP1 ChIP-seq peaks in 3T3-L1 cells at days 0 and 2 upon adipogenesis. Two
biological replicates (R1 and R2) were performed. b The overlap between KAP1 ChIP-seq peaks at days 0 and 2. c The fraction of distinct categories of
peaks (union of all KAP1 – KAP1.u, KAP1 present in at least two samples – KAP1.i, ZFP30, ZEB1, or p300) proximal to a gene encoding a KZFP. d KAP1,
ZFP30-HA, RNA PolII (POL2), p300/CBP, H3K4me1, and H3K27ac (K27Ac) ChIP-seq enrichments at the Pparg2 locus in 3T3-L1 cells (upper panel,
gray rectangle) or brown pre-adipocytes (lower panel, brown rectangle) at days 0 and 2 of adipogenic differentiation. e ChIP qPCR probing IgG or KAP1 in
3T3-L1 cells upon Zfp30 KD or shRNA control at days 0 and 2. The KAP1-bound Pparg and Zfp810 loci as well as a negative control were tested. n= 3
biologically independent experiments. **p < 0.01, t test. f Luciferase assay showing that KAP1 is essential for the identiﬁed Pparg2 enhancer activity.
Transcriptional activity as measured by luciferase assays (Fireﬂy/Renilla) for Pparg2-P and Pparg2-PdM (see Fig. 3g) at days 2 of adipogenic differentiation
upon Kap1 KD and rescue, as shown in Fig. 4d. n= 3 biologically independent experiments. **p < 0.01, t test. g, h Rescue of the differentiation defect in Kap1
KD and Zfp30 KO IBA cells, respectively, by ectopic expression of Pparg2. Pparg2 expression can be induced by Doxycycline (Dox). Differentiation was
assessed by lipid accumulation (ORO staining) while the protein levels were measured by western blotting. Note that there is already leaky expression
of Pparg2 when Dox is absent. All panels: error bars–SD. Source data are provided as a Source Data ﬁle
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will need to uncover the exact molecular mechanism that allows
KAP1 to function as a co-activator in this adipogenic context.
Finally, it has recently been shown that KAP1 haploinsufﬁ-
ciency triggers bistable obesity in mice, where the obesity state is
characterized by a reduced expression of an imprinted gene
network, including Nnat, Plagl1, and Peg367. However, it is not
clear whether this phenotype is a direct effect of KAP1 on adipose
tissue or not. In fact, only Peg3 among these three genes is dif-
ferentially expressed in Zfp30 KD 3T3-L1 cells (Supplementary
Data 1). Further, the conditional KO of KAP1 in mature adipo-
cytes (Adipoq-Cre) does not impact adiposity67, indicating that
KAP1 is not essential in fully differentiated adipocytes. However,
whether KAP1 impacts adipocyte differentiation was not known.
Here, we provide evidence that KAP1 is required for the differ-
entiation program in pre-adipocytes, and that one of its functions
depends on recruitment by ZFP30. Together, our ﬁndings provide
a new understanding of both adipogenic and KZFP–KAP1-
mediated gene regulation.
Methods
Cell culture. 3T3-L1 (ATCC), 293T (ATCC), and parental IBA cells32 were
cultured in the high-glucose DMEM medium (Life Technologies, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (Gibco), and 1× penicillin/
streptomycin solution (Life Technologies) in a 5% CO2 humidiﬁed atmosphere
at 37 °C and maintained at less than 80% conﬂuence before passaging. Primary
KAP1loxp/loxp MEF was generated from embryos and cultured in the same condi-
tion, as mentioned above.
Generation of knockout IBA cells. Zfp30 KO IBA cells were generated using the
CRISPR/Cas9 technology29,30. The targeting sequence was: 5′-
GTGCCTGAGTGCCTACGAGA-GGG (the last GGG is the PAM sequence)-3′.
Two days after transfection of the sgRNA and hCas9-Blasticidin (kindly provided
by Dr. Jiahuai Han) bearing plasmids, the cells were selected with 8 µg/ml Blas-
ticidin S HCl (#A1113903, Gibco) for 3 days. The selected cells were plated on 96-
well plates in a series of dilutions to achieve a single cell per well. The grown-up
clones were screened for Zfp30 KO and WT by genomic PCR followed by DNA
PAGE electrophoresis. The sequences of the screening primers were:
TGGCCGTGGTGTCTCTTCTCA and GAGGTGACCATTCTAAACCACAAAG.
Clones showing no wild-type band and those showing only wild-type bands were
then chosen and the PCR products were subjected to TA cloning (K202020,
Invitrogen). Ten TA clones from each IBA clones were subjected to Sanger
sequencing. Among them, four clones carrying missense and frame-shift muta-
tions, but not the wild-type allele, were identiﬁed as Zfp30 KO; and ﬁve clones
carrying only the wild-type allele were identiﬁed as Zfp30 WT. We did not ﬁnd any
cells carrying more than two mutated alleles among all the cells that we analyzed,
which shows that IBA cells are a diploid, at least at the Zfp30 genomic locus.
The IBA cells containing a ZFP30-binding motif deletion in the focal Pparg
enhancer were generated by the same approach with some modiﬁcations. Two
sgRNA sequences (sg1: TTCAATAATCATTCTGCTTA-GGG and sg2:
CTTCTCCAAATAAATGATTT-GGG) were cloned into PX458 (Addgene
#48138), respectively. IBA cells were transfected with these two plasmids together,
and the GFP+ cells were single-cell sorted into 96-well plates 48 h post
transfection. Afterward, the downstream procedure is the same as detailed above
for generating Zfp30 KO cells. The sequences of the screening primers were:
AGAGAAATGCCAACTGAGTGA and TCCTCTTCAAGAACAGTGGGT.
Candidate clones were further validated by TA cloning and Sanger sequencing. The
resulting Pparg2-M1 KO clone used in this study contains a 43 -bp deletion. To
explore whether, next to ZFP30, other adipogenic TFs may possibly bind to this
fragment (and additional 10 bp in each end), we performed a PWM scan for
adipogenesis-related (GO:0003700 DNA-binding transcription factor activity and
containing lipid or fat terms in their GO annotation) TFs derived from the mouse
motif database HOCOMOCO (34 TFs, Supplementary Data 7)68 and the vertebrae
database JASPAR (33 TFs, Supplementary Data 7)69 using FIMO (default settings)
70, revealing no signiﬁcant hits.
Generation of the Zfp30tm3e mice. Zfp30tm3e targeted ES cells were purchased
from the European Conditional Mouse Mutagenesis Program34. These cells were
injected into B6 Albinos blastocysts, and chimeric male mice were bred to B6
Albinos female mice. The offspring carrying the Zfp30tm3e allele were identiﬁed by
genotyping and bred to C57BL/6J mice. The genotyping primers are listed below:
Zfp30-tm2a-qF: GTTCACAGTGCCAAATTCTGG
Zfp30-tm2a-qR: AGGTGGAGTTCAGGGTCAG
Neo-F: CCTGAATGAACTGCAGGACG
Neo-R: GTTTCGCTTGGTGGTCGAAT
The Zfp30tm3e allele shows a band at 250 bp and wild-type allele at 125 bp. The
whole targeting cassette was validated by long-range PCR using SequalPrep Long
PCR kit (Applied Biosystems) followed by Sanger sequencing.
Human SVF cells. The human SVF cells were extracted with a previously described
method36. Brieﬂy, 50 ml of fresh lipoaspirates were washed twice with 40 ml of
DPBS Ca+/Mg+(Gibco #14040091) in 100 -ml syringes (VWR International #720-
2528) and subsequently incubated with 0.28 U/ml of liberase (Roche #05401119001
(ROC)) for 45 min at 37 °C under agitation. The digested tissue was mixed with
40 ml of 1% human albumin (CSL Behring) in DPBS Ca–/Mg– (Gibco #14190094)
and shaken to liberate the stromal cells. The aqueous phase was recovered and
centrifuged at 400 g for 5 min at RT. The cell pellet was resuspended in 15 ml of
remaining buffer and ﬁltered through a 100-μm and then 40-μm cell strainer. The
cell suspension was centrifuged and resuspended in 5 ml of 5% human albumin
(CSL Behring). The viability and the number of nucleated cells in the obtained cells
suspension were determined using a Nucleostainer, after which a red blood cell
lysis was performed using VersaLyse solution (Beckman Coulter #A09777)
according to the producer’s recommendations.
RNA interference and rescue. The pLKO.1-based shRNA was purchased from
Sigma.
>mouse shZfp30_1 (sigma: TRCN0000084321)
CCTGTTAGTCTCTATCAGAAA >mouse shZfp30_2 (sigma:
TRCN0000084322)
CGTGGGAAATAATGGGAAGAA >mouse shZfp30_3 (sigma:
TRCN0000084318)
GCCATGATAGACTGGCTTGTA >mouse shKap1 (Sigma:
TRCN0000071363)
CCGCATGTTCAAACAGTTCAA > human shZFP30-1 (sigma:
TRCN0000107910)
CCTCCTAATGTGCTACAGTAA > human shZFP30-2 (sigma:
TRCN0000107911)
GCCTTTAGAGTTAGAGGACAC > human shZFP30-3 (sigma:
TRCN0000107912)
CGTCGTTACTCAGAACTTATT > human shZFP30-4 (sigma:
TRCN0000107913)
CGACAACAACTTACTTTCCAT > human shZFP30-5 (sigma:
TRCN0000107914)
AGTACGACAACAACTTACTTC
The lentivirus vector for KAP1 KD and rescue was described previously66. They
derived from the pSicoR-Ef1a-mCh (Addgene #31847). Hairpin sequence against
murine Kap1 (5′-CCGGCCGCATGTTCAAACAGTTCAACTCGAGTTGAACTG
TTTGAACATGCGGTTTTTG-3′) or ﬁreﬂy luciferase (fLuc) were cloned in the
HpaI/XhoI sites for creating the shControl and shKap1 lentiviral vectors,
respectively. For the rescue-Kap1 plasmid, a Kap1 CDS containing a codon-
optimized shRNA-resistant was cloned in the shKap1-bearing pSicoR-Ef1a-mCh
vector to replace mCherry CDS. The rescue-ZFP30 (human) plasmids with human
shZFP30-1 were generated in the same manner.
Lentivirus production and infection. Pre-conﬂuent HEK293T cells were trans-
fected with lentiviral vectors carrying cDNAs or shRNAs of interest and second
generation of lentivirus-packing plasmids by the calcium phosphate precipitation
method. The cell culture medium was changed in 12 h, and the virus-containing
medium was collected 48 h post transfection.
For infection, a 1:1 ratio of virus-containing medium and fresh medium with
Polybrene (ﬁnal concentration at 10 μg/ml) were added to target cells at the density
~30–50%. The plates were centrifuged at 1500 g for 30 min and returned to the
cell incubator. The infectious medium was changed 12 h later. A mock infection
without a virus was included in each experiment.
Adipogenic differentiation. 3T3-L1 or IBA cells were induced to differentiation at
day 0 (2 days post conﬂuence) by adding the induction medium, which is the
complete culture medium supplemented with the MDI cocktail (1 μM dex-
amethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 167 nM insulin, all from
Sigma, Saint Louis, MO). At day 2, the induction medium was removed and the
maintenance medium (the complete culture medium supplemented with 167 nM
insulin) was added. At day 4, the maintenance medium was removed, and complete
culture medium was added. The cells were harvested for staining or RNA
extraction at day 6.
The isolated human SVF cells were then plated and cultured with MEM alpha
(Gibco #32561037) supplemented with 5% human platelet serum and 50 µg/ml
Primocin (InvivoGen #ant-pm-1). Once conﬂuent, the cells were subjected to
differentiation by exposing to the induction medium (the high glucose DMEM,
10% FBS, 50 μg/ml Primocin, 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM
dexamethasone, 1.7 μM insulin) for 7 days and subsequently the maintenance
medium (the high glucose DMEM, 10% FBS, 50 μg/ml Primocin, 1.7 μM insulin)
for another 7 days.
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Lipid staining. Fixed cell lipid staining was performed using ORO. In total, 30 ml
of 0.3% of the ORO stock solution (in isopropanol) was added to 20 ml of deio-
nized water. The solution was ﬁltered with ﬁlter paper and used as a working
solution. Cells were washed with PBS twice and ﬁxed with 10% formalin at room
temperature for 30 min. Then they are washed with 60% isopropanol once, and
stained with the ORO working solution for 10 min. The solution was poured off,
and the cells were rinsed with water until the water run cleared. The cells were then
scanned by image scanner or imaged under a microscope. For quantiﬁcation,
images were split into red, green, and blue channels by the Split Channels function
in Fiji. The lipid accumulation was scored by the intensity of red channel sub-
tracted from the average of those from green and blue channels.
Live cell lipid staining was performed using BODIPY 493/503 (D3922,
Invitrogen). BODIPY and Hoechst were added directly to the cell culture medium
for 15 min with ﬁnal concentration at 1 μg/ml and 5 μg/ml, respectively. Then the
medium was changed with the fresh medium, and the cells were imaged under a
Leica DMI4000. The lipid (green channel) and nucleus (blue channel) intensity of
human SVF cells were quantiﬁed by ImageJ/Fiji.
RNA extraction and qPCR. RNA extractions were performed using the Direct-zol
RNA Miniprep kit (R2052, Zymo Research). Potential genomic DNA con-
tamination was eliminated by DNase I digestion. The RNA quality and con-
centration was checked by Nanodrop spectrophotometer (Thermo Scientiﬁc).
One microgram of total RNA was used for single-strand cDNA synthesis using
the SuperScript VILO cDNA Synthesis kit (Life Technologies). The cDNA was
diluted 40 times, and 2.5 µl was used for qPCR. qPCR reactions were assembled
using PowerUp SYBR Green Master Mix (ThermoFisher Scientiﬁc) with three
technical replicates. The qPCR was performed using the QuantStudio 6 Flex qPCR
system (Applied Biosystems). Primers were checked for linearity and single-
product ampliﬁcation. The sequences of the primers are listed below:
Mouse Zfp30-1: forward-CATGGCTCATAGTACGGTG; reverse-TACAGAT
CCCTCTCGTAGG
Mouse Zfp30-2: forward-AAGCCAGATGTGATCACCCT; reverse-GCCACG
CCTTTGAATTCTTC
Mouse Pparg2: forward-CACCAGTGTGAATTACAGCAAATC; reverse-AGC
TGATTCCGAAGTTGGTG
Mouse AdipoQ: forward-TGGGGACCACAATGGACTCTA; reverse-TGGGC
TATGGGTAGTTGCAGT
Mouse Hprt1: forward-ATACCTAATCATTATGCCGAGG; reverse-AGCAAG
TCTTTCAGTCCTG
Mouse Fabp4: forward-CATCAGCGTAAATGGGGATT; reverse-GTCGTCTG
CGGTGATTTCAT
Human ZFP30: forward-CAAGCCATTCTCCTCCCTCA; reverse-ATGAAGT
GAGAGTCGGGCAT
Human ADIPOQ: forward-CCATACCAGAGGGTAAGAGCA; reverse-CCAG
CAACAGCATCCTGAG
Human HPRT1: forward- CGAGCAAGACGTTCAGTCCT; reverse-TGACCT
TGATTTATTTTGCATACC
To quantify the transcript derived from the ZFP30-bound L1MC5a in the Pparg
locus, a similar procedure was applied, except that random hexamers were used for
reverse transcription. The primers are the same as those used to perform ChIP-
qPCR at this Pparg locus and as listed in the ChIP-qPCR Methods section.
Zfp30-2 primers were used to perform qPCR on ZFP30tm3e mouse tissues and
qPCRs shown in the left panel of Supplementary Fig. 1D. Zfp30-1 primers (one
primer matches the junction of the CRISPR/Cas9 targeting site, thus is sensitive to
the KO alleles) were used for all the other qPCR experiments.
In vivo adipogenesis assay. The in vivo experiments were performed as described
previously20 by using the shRNAs listed above. Brieﬂy, fat tissue was dissected,
minced, and incubated in collagenase type II for 1 h at 37 °C. Approximately 106
cells were treated with virus and resuspended in 100 μl of Matrigel (BD Biosciences,
San Jose, CA) before injection subcutaneously into a skin fold of the neck. After
6 weeks of high-fat diet, Matrigel pads were excised. From each pad, pictures of
three full sections were taken, and adipocyte numbers as well as the number of
nuclei were determined automatically using the Cell Proﬁler Software. All
experiments were performed in three replicates, and the signiﬁcance of the
observed changes was estimated using a one-sided Wilcoxon rank-sum test.
mRNA-seq. The total RNA was checked for quality by Fragment Analyzer
(Advanced Analytical). High-quality samples (RQN > 8) were used to prepare the
library using the TruSeq RNA Library Prep Kit v2 (Illumina). Libraries were
checked for quality and quantiﬁed using the Fragment Analyzer and Qubit
(ThermoFisher Scientiﬁc), respectively, before being sequenced on Nextseq 500
(Gene expression core facility, EPFL). Two biological replicates were performed for
each condition.
mRNA-seq analysis and TE expression analysis. Fastq ﬁles containing paired-
end (ZFP30 KD and control samples in 3T3-L1 cells) and single-end (ZFP30 KO
and control samples in IBA cells) sequenced tags (reads) from two replicate
experiments each, were analyzed. Reads from each sample were trimmed, ﬁltered,
and checked for quality using trim_galore 0.4.0 (cutadapt and FastQC)71 with the
parameters -q 20 --fastqc --stringency 3 -e 0.05 --length 36. The retained tags were
aligned to the Ensembl 84 gene annotation of the NCBI38/mm10 mouse genome
using Bowtie 0.12.9 and the parameters -a --best --strata -S -m 100. Expression
levels per transcript and gene were estimated using mmseq-1.0.872 with default
parameters. Quantile normalized expression estimates were transformed into
pseudo-counts by un-logging, un-standardizing, and multiplying with gene length.
Pseudocounts were then normalized using mean-variance modeling at the obser-
vational level, as implemented in the voom() function in limma_3.30.473. Differ-
ential expression was computed on the normalized values using the limma_3.30.4
pipeline at an FDR of 0.1 and fold-change cutoff of 2 (|FC|). Heatmaps displaying
row-normalized (z-score transformation) expression values were generated using
the function heatmap.2() in gplots_3.0.1. Averages of the normalized expression
values (log2, before the z-score transformation) are displayed as an additional
sidebar left of the respective heatmaps.
For the TE analysis, reads (paired-end, 2 × 100 bp) were mapped to the
mouse (mm10) genome using hisat2 with parameters hisat2 -k 5 --seed 42 -p 774.
Counts on genes and TEs were generated using featureCounts75. To avoid read
assignment ambiguity between genes and TEs, a gtf ﬁle containing both was
provided to featureCounts. For repetitive sequences, an in-house curated
version of the Repbase database was used (fragmented LTR and internal
segments belonging to a single integrant were merged). Only uniquely mapped
reads were used for the quantiﬁcation. Finally, the features for which the add
up of reads across all samples was lower than the number of samples were
discarded from the analysis. Normalization for sequencing depth was done for
both genes and TEs using the TMM method as implemented in limma73 and
using the counts on genes as library size. Differential gene expression analysis
was performed using limma voom73. A TE was considered to be differentially
expressed when the fold-change between groups was > 2 and the p-value < 0.05.
A moderated t test (as implemented in R limma) was used to test signiﬁcance.
P-values were corrected for multiple testing using the Benjamini–Hochberg’s
method76.
Chromatin immunoprecipitation (ChIP). Chromatin immunoprecipitation was
performed as previously described77. Brieﬂy, 2 × 15 cm dishes of cells were cross-
linked with 1% formaldehyde at room temperature for 10 min. The cross-linking
was quenched by fresh glycine at a ﬁnal concentration of 0.15 M. The cells were
then harvested and lysed in a series of ice-cold lysis buffer to collect the nuclei. One
mililiter of nuclei suspension was transferred to Covaris 1 -mL glass tube and
sonicated at 10% duty factor, peak incident power 140W, and cycle per purst 200
for 20 min in Covaris E220. In total, 20 µl of the sonicated chromatin was de-cross-
linked and the DNA was extracted for quality control. The majority of the DNA is
~200 bp. Those that passed the quality control were divided into 25 µg of DNA in
each aliquot and 1 µl was kept as input. Overall, 75 µl of magnetic protein G beads
coupled with 10 µg of anti-HA (ab9110, Abcam), anti-KAP1 (KAP1-a1: ab10483
(Abcam), KAP1-a2: ab22553 (Abcam)), anti-p300 (sc-585, Santa Cruz), or anti-IgG
control antibody (12-371, Millipore) was incubated with each aliquot of chromatin
overnight at 4 °C. The beads were then washed and subjected to different pro-
cessing listed below:
ChIP-qPCR: the chromatin precipitated by the beads, together with the input
chromatin were digested with Proteinase K and RNase, then subjected to de-cross-
linking by heating at 65 °C overnight. The DNA was then puriﬁed using the
Agencourt AMPure XP (Beckman Coulter). qPCR was performed as mentioned
before. Note that the ChIP-ed DNA was normalized to the input DNA, leading to
the %input value. The primers are listed below:
Pparg: forward-TCTTCGTGTTATAAACCCAAATCA; reverse-GGGTTCTAA
AACCTTCATCATCTC
Zfp810: forward-CTGACCTACACTGGAATGCC; reverse-TCACAGGACTCA
TACAGGTGA
Control: forward-GGGTGCTAGCCTTCCTGACT; reverse-TCCAAGGTTCTC
CCGACATA
Rasgfr1: forward-CTGCTGCTCCCACATCCA; reverse-GCAGTCGTGGTAGT
TGTA
Zfp316: forward-TTCATGTGCGTGAGGAGG; reverse-AAGCGTTTCTCTCA
GCGA
Grb10: forward-CATACGTGTTACATGCGC; reverse-TGTCGGTTCGTTTAG
GAG
ChIP-seq: the ChIPmentation method78 was used to generate the ChIP-seq
library. In brief, the chromatin precipitated by the beads was subjected to Tn5
transposase-mediated tagmentation and adapter ligation at one single step. Then
the tagmentated chromatin was digested with Proteinase K and RNase, then de-
cross-linked by heating at 65 °C overnight. The DNA was then puriﬁed using the
Agencourt AMPure XP beads, and ampliﬁed using the KAPA HiFi Hotstart
ReadyMix kit (KAPA Biosystems) and Nextera Index (Illumina) primer sets for 15
cycles. The PCR product was size-selected using Agencourt AMPure XP beads,
quality checked using Fragment analyzer, quantiﬁed by Qubit, and then be
sequenced on Nextseq500 (Gene expression core facility, EPFL). Two biological
replicates were applied to each condition.
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ChIP-exo experiments of human ZFP30 in HEK293T were performed as
previously described46. In brief, ChIP was performed using 15 μg of anti-HA.11
antibody (clone 16B12, Covance) and protein G dynabeads (ThermoFisher). ChIP-
exo was then performed on bead-bound chromatin, with adaptations for use in 96-
well plates and Illumina sequencing. The original protocol was followed with the
following modiﬁcations: we used protein G coupled to magnetic beads instead of
sepharose; we doubled the amount of washes, but used only 200 μl instead of 1 ml;
we used Ampure-based instead of column-based cleanup and size selection steps.
ChIP-seq analysis. The ChIP-seq tags were aligned to the NCBI38/mm10 genome
with Bowtie279 and the parameters ‘--very-sensitive -p 8′. Duplicates were
removed, as well as the reads with a mapping quality under 10. Regions showing
signiﬁcant ChIP enrichment (peaks) were determined with Homer42 (‘-F 2 -L 3
-localSize 5000 -C 4 -fragLength 200 -minDist 500 -center’) using matched IgG (for
ZFP30-HA and KAP1) and input (for p300, available from20) samples as controls.
ZFP277-HA was additionally employed as a negative control based on its lack of
localization to the nucleus, as previously described20: all regions overlapping
ZFP277-HA peaks were removed from the analysis. Given the large variability in
peak numbers between replicates at individual days despite high correlations of
ChIP enrichments between the replicates (Supplementary Fig. 2E) and the fact that
often, peaks called in a single replicate at day 0 were also detected in at least one
replicate at day 2, we merged ZFP30 and KAP1-bound regions into either the
union of all regions (union, u, Figs. 2h, 5b) or the intersection of at least two
regions, irrespective of the day (in2, I, Supplementary Figs. 2H, 5C), respectively.
When comparing differences in binding at the 2 days, we considered both peak
numbers but also took a more quantitative approach, in which read counts con-
tained in the genomic intervals deﬁned by ZFP30 or KAP1 binding, respectively, at
day 0 to day 2 were compared using DESeq2 1.14.180 with padj ≤ 0.15, |FC| > 2.
Shared and D0 or D2-speciﬁc peak numbers were displayed using the R package
VennDiagrams 1.6.17. Library-size normalized ChIP-seq tags were visualized using
Gviz 1.18.2 (Figs. 2i, 5d; Supplementary Figs. 2I, 5D). Log2-transformed library-
size normalized DNAse I and H3K4me1 ChIP-seq tags in a 4 -kb large region
centered around the point of maximal ZFP30-binding (peak summit) were aver-
aged and displayed in Fig. 2j (for differential ZFP30 peaks) and Supplementary
Fig. 2J (constitutive ZFP30 peaks).
Motif analysis. For both mouse and human, motif discovery was performed using
MEME 4.12.0 as part of the MEME-ChIP suite70 (‘-nmotifs 3 -minw 15 -maxw 45
–dna -revcomp) on 400 bp centered on the summits of all ZFP30-bound regions. In
mouse, the set containing the intersection of at least two regions, irrespective of the
day, was used (in2). ROC curves were calculated similarly to ref. 41. Brieﬂy, we
considered a set of p, positive sequences of length l (ZFP30 peak sets, union) and a
set of n negative sequences of length l (shifted ZFP30 sequences). All sequences
were scored for the motif using Fimo (in MEME-ChIP suite) with the parameters
--output-pthresh 0.1 and considering only the best-scoring motif hit/sequence, thus
obtaining two vectors of p and n scores. The statistic w of a Wilcoxon-test between
both vectors was computed and used to display the ROC curves in Supplementary
Fig. 2N and compute the AUC as w /(n x m). The fraction of peaks with motifs
displayed in Supplementary Fig. 2O corresponds to motif hits obtained using Fimo
and the parameters—output -pthresh 0.001. To determine which TFs potentially
co-bind with ZFP30, we expanded our motif analysis using HOMER ﬁndMotifs
with the parameters mopt= “-len 6,8,10,12,14,16 -size 100”, reporting known
motifs in Supplementary Data 5.
Other computational analyses. All computational analyses were performed using
R version 3.3.2 and Bioconductor version 3.4. All t tests were unpaired if not
otherwise speciﬁed. ZFP30-bound regions and regulated genes were annotated
using Ensembl 84, either by direct download or through biomaRt_2.30.081. The
Gene Ontology enrichment analysis was performed using the topGO 2.26.0
package, the elimCountmethod and a p-value cutoff of 0.001. Repeat elements were
obtained by scanning with RepeatMasker version 4.0.5 with the parameters -s
-nolow -norna -species mammal -xsmall -html -gff. Repeat enrichment was obtained
by comparing the fraction of ZFP30 peaks vs. shifted regions (same length and
number) overlapping (1 bp) repetitive elements.
Publicly available data. We used the following publicly available data: (1) in 3T3-
L1 cells: ChIP-seq using antibodies against RNA PolII, H3K4me1, H3K27ac, ZEB1,
p300, C/EBPbeta, C/EBPalpha, RXR, PBX1, VDR, KLF5, ATF2, FOSL2, JUND, C/
EBPalpha, STAT5A, cJUN, KLF4, ATF2, ATF7, GR, PAPRG, STAT1, and DNase-
seq;20,38,39,43,44 note that one replicate of H3K27ac data (day 2) is excluded
from the analysis due to low quality. (2) In a brown pre-adipogenic cell line: RNA
PolII, H3K27ac, and CBP53. Except for Supplementary Fig. 2R, where the original
reported peaks were used, ChIP-seq and DNase-seq data were reanalyzed analo-
gous to the in-house generated data.
MITOMI. The zinc ﬁnger domains of ZFP30 (amino acids 177–548) were cloned
into pF3A–eGFP in vitro expression vector by Gateway cloning. The protein was
expressed in vitro using 12 µl of the TNT SP6 High-Yield Wheat Germ protein
expression system (Promega) and 4 µl of plasmid with concentration 200 ng/µl.
In total, 1 µl of the reaction was mixed with 4 µl of target DNA and loaded into
MITOMI chamber. All target DNA fragments were obtained as single-stranded
oligonucleotides listed below:
ChIP-seq consensus:
AGACACAGCTGAAGAGAGAATTAGAGAAATGGAAGA
motif at PPARg: GGAGAAGAGATGATGAAGGTTTTAGAACCC
control: ATTTGAGGGACCAACGCATGCAAGTCTTACTTTTAA
Each oligonucleotide contained a common 3′-prime end: CGTATGCCGTCT
TCTGCTTG. These oligonucleotides were subsequently used to generate
ﬂuorescently labeled double-stranded DNA as described previously40 with Cy5-
labeling primer: Cy5-CAAGCAGAAGACGGCATACG.
The molds for microﬂuidic devices and devices themselves were adapted from
MITOMI40 as described previously41 with minor modiﬁcations: the design did not
contain capillary pumps for loading DNA and protein samples into MITOMI
chambers. Instead, the samples were loaded by pressurizing the corresponding
inlets of microchips. The designed microchips were fabricated using two-layer soft
lithography, as described before40. The surface chemistry, MITOMI, and image
acquisition were performed as described previously40. We quantiﬁed the amount of
each target sequence bound to the respective TF at the equilibrium state by means
of ﬂuorescence in a range of input DNA concentrations in at least three replicates.
The difference between the Cy5 signal in and outside MITOMI button normalized
by GFP signal (corresponding to the amount of immobilized protein) was
calculated for each concentration. The obtained binding curves for each sequence
were then ﬁtted by use of one-site equilibrium binding equation.
Luciferase reporter assay. Exo III-assisted ligase-free cloning method82 was used
to clone the Zfp30-binding sequence of the targets into pGL3-promotor vector
(Promega), between the NheI and BglII restriction sites. The primers to amplify the
target sequences are listed below:
Tec: forward-cttacgcgtgctagcGGTGACTGAGAAGAAGCCCA; reverse-gcagatc
gcagatctGGTCGTCAAAGCAATGCCTT
Plscr2: forward-cttacgcgtgctagcCGTGAGCTCGTTCTTCTTGG; reverse-gcagat
cgcagatctTGCTCCTCGTTTCCAGTTCT
Myof: forward-cttacgcgtgctagcCTCGTGGAGAAAGCAAGTCG; reverse-gcaga
tcgcagatctTCGAGAATAGTGGACAGCCC
Col28a1: forward-cttacgcgtgctagcTTCAGCCCTGCAAGTGATTG; reverse-gcag
atcgcagatctTCCCTTCCCCTTTCCCTTTC
Ahnak: forward-cttacgcgtgctagcGGCCAGCACAGAAAGACTTC; reverse-gcag
atcgcagatctTGGAACTGCAGCTGGTTGTA
Pparg: forward-cttacgcgtgctagcATTTGAGGGACCAACGCATG; reverse-gcaga
tcgcagatctTGGGGTCAATTCTCAAGCCT
Angptl4: forward-cttacgcgtgctagcCACCTAAAGCCTACCCCACA; reverse-gca
gatcgcagatctCCCTTCTTGACATCTGTGGC
Cidec: forward-cttacgcgtgctagcTCCAACAGGTGAGCAGACAT; reverse- gcaga
tcgcagatctCAGCCCGGGTACTTCTCTAC
To generate the Pparg2-P luciferase reporter, 9.5 kb of DNA upstream the
Pparg2 TTS was cloned. The Pparg2-PdM and Pparg2-PdP were generated by
mutagenesis from the Pparg2-P fragment. All the DNA fragments were cloned into
the pGL3-basic vector (Promega), using the XhoI and HindIII restriction sites. The
primers are listed below:
For Pparg2-P:
Pparg-F1: tagcccgggctcgagCCAGTAGGAACTGCATTTCAGAGT
Pparg-R1: cggaatgccaagcttGAATCTCCCAGAGTTTCACCCATAAC
For Pparg2-PdM fragment1:
Pparg-F1: shown above
mutation-R: TCCAAATAAATGATTTGGGTTTATAACACGAAGA
For Pparg2-PdM fragment2:
Mutation-F: ATAAACCCAAATCATTTATTTGGACCCTAAGCAGAATGAT
TATTGAAACTGAG
Pparg-R1: shown above
For Pparg2-PdP:
Pparg-F2: tagcccgggctcgagCATGAGTGTCACAGTAACTGCACA
Pparg-R1: shown above
Note that the bases in lowercase are the overhang sequences used to anneal with
the vector.
Immunoprecipitation and western blotting. Cells were lysed with lysis buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
TritonX-100, 2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 1 mM
Na3VO4) on ice for 15 min. Cell lysates were then centrifuged at 20,000 g for
30 min. The supernatant was immunoprecipitated with 20 µl of mouse anti-HA-
agarose beads (A2095, Sigma) at 4 °C for 3 h or overnight. After the immuno-
precipitation, the beads were washed four times in lysis buffer, and the immuno-
precipitated proteins were subsequently eluted by 1× SDS sample buffer at room
temperature for 10 min. The supernatant was collected and denatured at 100 °C for
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2 min. The samples were subjected to western blotting with the corresponding
antibodies. Rabbit anti-Flag (F7425, dilution 1:1000), mouse anti-α-tubulin (T5168,
1: 5000), and mouse anti-HA antibodies (H3663, dilution 1:1000) were purchased
from Sigma. Rabbit anti-HA (ab9110, dilution 1:1000) and mouse anti-KAP1
(ab22553, dilution 1:1000) were from Abcam. The uncropped western blot images
are provided in Supplementary Figure 6.
Bioethics. All mouse experiments were conducted in strict accordance with Swiss
law, and all experiments were approved by the ethics commission of the state
veterinary ofﬁce (60/2012, 43/2011). The work on human SVF cultures derived
from human lipoaspirate samples is approved by the ethical commission of Canton
Ticino (CE 2961 from 22.10.2015) and conforms with the guidelines of the 2000
Helsinki declaration. The anonymized samples were collected under signed
informed consent.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All RNA-seq and ChIP-seq data are available in the ArrayExpress database (www.ebi.ac.
uk/arrayexpress) under the accession numbers E-MTAB-6995 and E-MTAB-6817. The
uncropped western blots are provided in Supplementary Figure 6. The source data
underlying Figs. 1a-b, 1d, 1f, 1h-k, 2l, 3d, 3f, 3h-i, 3k, 4d-e, 5e-f, and Supplementary
Figs 1a-b, 1d, 1f-g, 1i, 1l, 2a, 2g, 3d-e, 3g, 5a, 5h-i are provided as Source Data ﬁle. All
other relevant data supporting the key ﬁndings of this study are available within the
article and its Supplementary Information ﬁles or from the corresponding author upon
reasonable request. A reporting summary for this article is available as a Supplementary
Information ﬁle.
Code availability
The codes used for the analysis are incorporated into the Methods sections listed above.
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